Harbinger Health Establishes RESOLVE™ as a New Category for Cancer Detection

Announces $100M financing to develop a portfolio of multi-cancer tests designed to reduce diagnostic uncertainty and delays

Apr. 14, 2026 at 10:23am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray-style image of a human blood cell, revealing its intricate internal structures and suggesting the complex biological processes involved in cancer detection.Harbinger Health's new RESOLVE™ tests aim to bring clarity to the often-uncertain period between cancer suspicion and diagnosis, potentially enabling earlier treatment.Cambridge Today

Harbinger Health, a biotechnology company pioneering cancer resolution, has announced RESOLVE™, a new category of blood-based multi-cancer detection tests designed to bring clarity to the often-uncertain period between suspicion of cancer and diagnosis. The company's $100 million financing raised in 2025 supports the development of the initial product portfolio, the ongoing PROCARES prospective validation study, and advancement of the Harbinger HX platform.

Why it matters

Approximately 80% of all cancers are diagnosed following the presentation of symptoms that are often confounding, and people who present with cancer symptoms wait an average of five months for a diagnosis, while mortality can increase by up to 8% for every month of delay in starting treatment. RESOLVE™ is intended to address this critical gap between presentation and diagnosis, minimizing false negatives, avoiding false positives, and providing actionable information on the cancer tissue of origin to enable faster clinical decision-making.

The details

RESOLVE™ is powered by the Harbinger HX platform and is designed to minimize false negatives that can allow early cancers to go undetected, avoid false positives that place unnecessary burden on patients and healthcare systems, and provide actionable information on the cancer tissue of origin. The company's $100 million financing raised in 2025 supports the development of the initial product portfolio, the ongoing PROCARES prospective validation study, and advancement of the Harbinger HX platform.

  • Harbinger Health announced RESOLVE™ on April 14, 2026.
  • The first products from the RESOLVE™ portfolio are expected to be commercially available in the second half of 2026.
  • The PROCARES prospective validation study is approaching full enrollment, with more than 88% of participants enrolled to date.

The players

Harbinger Health

A biotechnology company pioneering cancer resolution and introducing fundamentally new approaches to resolving cancer-related uncertainty across multiple clinical contexts.

Ajit Singh, Ph.D.

Chief Executive Officer of Harbinger Health and Flagship Pioneering CEO-Partner.

Doug Cole, M.D.

Co-Founder and Board Director of Harbinger Health and Managing Partner at Flagship Pioneering.

Flagship Pioneering

The company that founded Harbinger Health and led the $100 million financing round in 2025.

Got photos? Submit your photos here. ›

What they’re saying

“For most people who present with concerning symptoms, signs or findings, it takes months to get to a diagnosis, and mortality increases significantly with each month that goes by. RESOLVE™ helps clinicians move more quickly and confidently from cancer suspicion to diagnosis in people who show signs of disease, even in its earliest stages.”

— Ajit Singh, Ph.D., Chief Executive Officer of Harbinger Health and Flagship Pioneering CEO-Partner

“We are grateful to have the continued support of our investors who share our conviction in Harbinger's platform and team to open new and distinct possibilities in blood-based cancer detection. Since its founding, Harbinger has pioneered technology and methods that seek to address the most difficult challenges in cancer detection: performance, clinical utility and access.”

— Doug Cole, M.D., Co-Founder and Board Director of Harbinger Health and Managing Partner, Flagship Pioneering

What’s next

Harbinger Health's PROCARES prospective validation study is approaching full enrollment, with more than 88% of participants enrolled to date. The results from this study are expected to further validate the clinical performance of the RESOLVE™ tests and support their commercial launch in the second half of 2026.

The takeaway

Harbinger Health's RESOLVE™ category of multi-cancer detection tests aims to significantly reduce the time between cancer suspicion and diagnosis, enabling earlier treatment and potentially improving outcomes for patients. This innovative approach, backed by substantial funding and clinical evidence, represents a promising advancement in the field of cancer detection.